References
- 1. CHLOE PEK SANG TANG, JULIE MCMULLEN, CONSTANTINE TAM. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk. Lymphoma 2018;59(7):1554–1564.
- 2. MICHAEL HALLEK, TAIT D. SHANAFELT, BARBARA EICHHORST. Chronic lymphocytic leukaemia. Lancet 2018;391(10129):1524–1537.
- 3. SARJU GANATRA, AJAY SHARMA, SACHIN SHAH, GHULAM M. CHAUDHRY, DAVID T. MARTIN, TOMAS G. NEILAN, et al. Ibrutinib-Associated Atrial Fibrillation. JACC Clin. Electrophysiol. 2018;4(12):1491–1500.
- 4. FRANCESCA PISTOIA, SIMONA SACCO, CINDY TISEO, DIANA DEGAN, RAFFAELE ORNELLO, ANTONIO CAROLEI. The Epidemiology of Atrial Fibrillation and Stroke. Cardiol. Clin. 2016;34(2):255–268.
- 5. MICHAEL HUGHES, GREGORY Y.H. LIP. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb. Haemost. 2008;99(2):295–304.
- 6. RON PISTERS, DEIRDRE A. LANE, FRANCISCO MARIN, A. JOHN CAMM, GREGORY Y.H. LIP. Stroke and Thromboembolism in Atrial Fibrillation - Systematic Review of Stroke Risk Factors and Risk Stratification Schema - Circ. J. 2012;76(10):2289–2304.
- 7. WEN GEN ZHU, QIN MEI XIONG, KUI HONG. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Texas Hear. Inst. J. 2015;42(1):6–15.
- 8. GERHARD HINDRICKS, TATJANA POTPARA, NIKOLAOS DAGRES, ELENA ARBELO, JEROEN J BAX, CARINA BLOMSTRÖM-LUNDQVIST, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2021;42(5):373–498.
- 9. TAIT D. SHANAFELT, SAMEER A. PARIKH, PETER A. NOSEWORTHY, VALENTIN GOEDE, KARI G. CHAFFEE, JASMIN BAHLO, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk. Lymphoma 2017;58(7):1630–1639.
- 10. AVIRUP GUHA, AMIT K. DEY, HANI JNEID, JAVIER PINILLA IBARZ, DANIEL ADDISON, MICHAEL FRADLEY. Atrial Fibrillation in the Era of Emerging Cancer Therapies. Eur. Heart J. 2019;40(36):3007–3010.
- 11. FAISAL RAHMAN, DARAE KO, EMELIA J. BENJAMIN. Association of atrial fibrillation and cancer. JAMA Cardiol. 2016;1(4):384–386.
- 12. TRACY E. WICZER, LAUREN B. LEVINE, JESSICA BRUMBAUGH, JESSICA COGGINS, QIUHONG ZHAO, AMY S. RUPPERT, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739–1748.
- 13. DEBORAH M. STEPHENS, JOHN C. BYRD. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 2019;133(12):1298–1307.
- 14. IRIS DE WEERDT, SUZANNE M. KOOPMANS, ARNON P. KATER, MICHEL VAN GELDER. Incidence and management of toxicity associated with ibrutinib and idelalisib: A practical approach. Haematologica 2017;102(10):1629–1639.
- 15. BRONWYN C. THORP, XAVIER BADOUX. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. Leuk. Lymphoma 2018;59(2):311–320.
- 16. BRIAN A HEMMINGS, DAVID F RESTUCCIA. PI3K-PKB / Akt Pathway 2016; 1–4.
- 17. MARKUS C. STÜHLINGER, ANSGAR WELTERMANN, PHILIPP STABER, DANIEL HEINTEL, THOMAS NÖSSLINGER, MICHAEL STEURER. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. Wien. Klin. Wochenschr. 2019;
- 18. GARY TSE. Mechanisms of cardiac arrhythmias. J. Arrhythmia 2016;32(2):75-81
- 19. LYNETTE PRETORIUS, XIAO JUN DU, ELIZABETH A. WOODCOCK, HELEN KIRIAZIS, RUBY C.Y. LIN, SILVANA MARASCO, et al. Reduced phosphoinositide 3-kinase (p110α) activation increases the susceptibility to atrial fibrillation. Am. J. Pathol. 2009;175(3):998-1009.
- 20. JULIE R MCMULLEN, ESTHER J H BOEY. Correspondence To the editor : Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac. Blood 2014;124(25):3829–3831.
- 21. ROBERT JANKOV, KEITH TANSWELL. CORRESPONDENCE: Response. Pediatr. Res. 2003;53(1):200.
- 22. LE JIANG, LINLING LI, YANFEI RUAN, SONG ZUO, XIAOYAN WU, QIANQIAN ZHAO, et al. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Hear. Rhythm 2019;16(9):1374-1382
- 23. TRACY E WICZER, LAUREN B LEVINE, JESSICA BRUMBAUGH, JESSICA COGGINS, QIUHONG ZHAO, AMY S RUPPERT, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739–1748.
- 24. J. J. SHATZEL, S. R. OLSON, D. L. TAO, O. J.T. MCCARTY, A. V. DANILOV, T. G. DELOUGHERY. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J. Thromb. Haemost. 2017;15(5):835–847.
- 25. SEMRA PAYDAS. Management of adverse effects/toxicity of ibrutinib. Crit. Rev. Oncol. Hematol. 2019;136 (August 2018):56–63.
- 26. ASHER CHANAN-KHAN, PAULA CRAMER, FATIH DEMIRKAN, GRAEME FRASER, RODRIGO SANTUCCI SILVA, SEBASTIAN GROSICKI, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–211.
- 27. JOHN C BYRD, RICHARD R FURMAN, STEVEN E COUTRE, JAN A BURGER, KRISTIE A BLUM, MORTON COLEMAN, et al. ı ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015;125(16):2497–2507.
- 28. CARLOS AGUILAR. Ibrutinib-related bleeding: Pathogenesis, clinical implications and management. Blood Coagul. Fibrinolysis 2018;29(6):481–487.
- 29. GIUSEPPE BORIANI, PAOLO CORRADINI, ANTONIO CUNEO, ANNA FALANGA, ROBIN FOÀ, GIANLUCA GAIDANO, et al. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematol. Oncol. 2018;36(4):624–632.
- 30. RACHEL A. RIGG, JOSEPH E. ASLAN, LAURA D. HEALY, MICHAEL WALLISCH, MARISA L.D. THIERHEIMER, CASSANDRA P. LOREN, et al. Oral administration of bruton’s tyrosine kinase inhibitors impairs GPVI-mediated platelet function. Am. J. Physiol. - Cell Physiol. 2016;310(5):C373–C380.
- 31. L. S. QUEK, J. BOLEN, S. P. WATSON. A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Curr. Biol. 1998;8(20):1137–1140.
- 32. MARIE LEVADE, ELODIE DAVID, CÉDRIC GARCIA, PIERRE ALEXANDRE LAURENT, SARAH CADOT, ANNE SOPHIE MICHALLET, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood 2014;124(26):3991–3995.
- 33. ALESSANDRA SORIANI, B. MORAN, M. DE VIRGILIO, T. KAWAKAMI, A. ALTMAN, C. LOWELL, et al. A role for PKCθ in outside-in αIIb β3 signaling. J. Thromb. Haemost. 2006;4(3):648–655.
- 34. ANDREW H. LIPSKY, MOHAMMED Z.H. FAROOQUI, XIN TIAN, SABRINA MARTYR, ANN M. CULLINANE, KHANH NGHIEM, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 2015;100(12):1571–1578.
- 35. KHAI LI CHAI, GAIL ROWAN, JOHN F. SEYMOUR, KATE BURBURY, DENNIS CARNEY, CONSTANTINE S. TAM. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leuk. Lymphoma 2017;58(12):2811–2814.
- 36. HAKUOH KONISHI, YOUICHI KATOH, NORIHIDE TAKAYA, YUJI KASHIWAKURA, SEIGO ITOH, CHISEI RA, et al. Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury. Circulation 2002;105(8):912–916.
- 37. STEFFEN MASSBERG, MEINRAD GAWAZ, SABINE GRÜNER, VALERIE SCHULTE, ILDIKO KONRAD, DIETLIND ZOHLNHÖFER, et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J. Exp. Med. 2003;197(1):41–49.
- 38. JUDITH M.E.M. COSEMANS, MARIJKE J.E. KUIJPERS, CHRISTELLE LECUT, SARAH T.B.G. LOUBELE, SYLVIA HEENEMAN, MARTINE JANDROT-PERRUS, et al. Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions. Atherosclerosis 2005;181(1):19–27.
- 39. ARMIN J. REININGER, ISABELL BERNLOCHNER, SANDRA M. PENZ, CATHERINE RAVANAT, PETER SMETHURST, RICHARD W. FARNDALE, et al. A 2-Step Mechanism of Arterial Thrombus Formation Induced by Human Atherosclerotic Plaques. J. Am. Coll. Cardiol. 2010;55(11):1147–1158.
- 40. FREDERIK DENORME, SIMON F. DE MEYER. The VWF-GPib axis in ischaemic stroke: Lessons from animal models. Thromb. Haemost. 2016;116(4):597–604.
- 41. ISAAC B. RHEA, ALEXANDER R. LYON, MICHAEL G. FRADLEY. Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies. Curr. Oncol. Rep. 2019;21(5):1–11.
- 42. YUTAO GUO, HANG ZHU, YUNDAI CHEN, GREGORY Y.H. LIP. Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation. Am. J. Med. 2018;131(2):185–192.
- 43. L. KAZIANKA, C. DRUCKER, C. SKRABS, W. THOMAS, T. MELCHARDT, S. STRUVE, et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia 2017;31(5):1117–1122.
- 44. ALAINA VRONTIKIS, JESSICA CAREY, JEFFREY A. GILREATH, AHMAD HALWANI, DEBORAH M. STEPHENS, JOHN W. SWEETENHAM. Proposed algorithm for managing Ibrutinib-related atrial fibrillation. Oncol. (United States) 2016;
- 45. P. KIRCHHOF, STEFANO BENUSSI, DIPAK KOTECHA, ANDERS AHLSSON, DAN ATAR, BARBARA CASADEI, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016;37(38):2893–2962.
- 46. MICHAEL L. WANG, HUN LEE, HUBERT CHUANG, NICOLAUS WAGNER-BARTAK, FREDERICK HAGEMEISTER, JASON WESTIN, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56.
- 47. JENNIFER R. BROWN. How I treat CLL patients with ibrutinib. Blood 2018;131(4):379–386.
- 48. JOHN LEONARD FITZGERALD, LAURENCE GUY HOWES. Drug Interactions of Direct-Acting Oral Anticoagulants. Drug Saf. 2016;39(9):841–845.
- 49. ALLISON E. BURNETT, CHARLES E. MAHAN, SARA R. VAZQUEZ, LYNN B. OERTEL, DAVID A. GARCIA, JACK ANSELL. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J. Thromb. Thrombolysis 2016;41(1):206–232.
- 50. ZAIN AL-JAMMALI, BRENT BECKNER, JOSEPH BUBALO. Ibrutinib-Related Atrial Fibrillation: An Anticoagulant Challenge. JHOPonline.com l J. Hematol. Oncol. Pharm. 2019;9(2):47–50.
- 51. FREDERICK A. MASOUDI, HUGH CALKINS, CLIFFORD J. KAVINSKY, JOSEPH P. DROZDA, PHILLIP GAINSLEY, DAVID J. SLOTWINER, et al. 2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview. J. Am. Coll. Cardiol. 2015;66(13):1497–1513.
- 52. DAVID R. HOLMES, SAIBAL KAR, MATTHEW J. PRICE, BRIAN WHISENANT, HORST SIEVERT, SHEPHAL K. DOSHI, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. J. Am. Coll. Cardiol. 2014;64(1):1–12.
- 53. VIVEK Y. REDDY, SVEN MÖBIUS-WINKLER, MARC A. MILLER, PETR NEUZIL, GERHARD SCHULER, JENS WIEBE, et al. Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: The ASAP study (ASA plavix feasibility study with watchman left atrial appendage closure technology). J. Am. Coll. Cardiol. 2013;61(25):2551–2556.
- 54. TERESA LÓPEZ-FERNÁNDEZ, ANA MARTÍN GARCÍA, ANA SANTABALLA BELTRÁN, ÁNGEL MONTERO LUIS, RAMÓN GARCÍA SANZ, PILAR MAZÓN RAMOS, et al. Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations. Rev. Esp. Cardiol. 2017;70(6):474–486.